The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse IRS-CD2-Safety, tolerability
- collapse A double-blind, randomised, two-way crossover single-centre pharmacokinetic interaction (phase I) study of repeated oral doses of AZ 242 (3 mg) and a single oral dose of warfarin (25 mg) in healthy male subjects
- collapse A phase I study to investigate the safety and pharmacokinetics of AZ242 after repeated oral dosing (3 mg once daily) in healthy male Japanese subjects (single-blind, rondomized, placebo-controlled, parallel group study)
- collapse A single-centre, open, randomised, three-way crossover drug-drug interaction study of AZ 242 8 mg and glibenclamide 3.5 mg after single oral administration in healthy male subjects (Phase I)
- collapse A single-centre, open, randomised, two-way crossover, phase I interaction study to assess the effects of ketoconazole 200 mg once daily on the pharmacokinetics of a single dose of AZ 242 8 mg, when administered to healthy male subjects
- collapse A double-blind, randomised, single-centre, placebo-controlled, cross-over phase I study to investigate renal function in healthy male subjects, after repeated oral dosing of 3 mg AZ 242
- collapse A single-centre, open, randomised, three-way crossover drug-drug interaction study of AZ 242 tablet 3 mg and metformin tablet 500 mg bid after repeated oral administration in healthy male subjects (Phase I) Author: Eric Evene, Aster
- collapse A single-centre, open, randomised, three-way crossover drug-drug interaction study of AZ 242 tablet 3 mg and digoxin tablet 0.25 mg after repeated oral administration in healthy male subjects (Phase I)
- collapse A Study to investigate the effect of food on PK and safety of AZ242 (single oreal dose of 3 mg) in healthy male Japanese subjects
- collapse IRS-CD2-kidney
